ClinicalTrials.gov
ClinicalTrials.gov Menu

Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03340350
Recruitment Status : Recruiting
First Posted : November 13, 2017
Last Update Posted : May 1, 2018
Sponsor:
Collaborator:
Creighton University
Information provided by (Responsible Party):
Sriram Ramaswamy, VA Nebraska Western Iowa Health Care System

Brief Summary:
The study will evaluate the safety and efficacy of adjunctive minocycline treatment in veterans with PTSD.

Condition or disease Intervention/treatment Phase
PTSD Drug: Minocycline Phase 4

Detailed Description:
This is a 12-week, open-label pilot study in which adjunctive minocycline will be administered to approximately 15 veterans diagnosed with PTSD.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans
Actual Study Start Date : May 10, 2017
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Minocycline
Minocycline 100 mg/day 1 to 7 and 200 mg/day 8 to end of week 12
Drug: Minocycline
Minocycline capsule
Other Name: Minocycline hydrochloride capsule




Primary Outcome Measures :
  1. PTSD Symptoms [ Time Frame: 12 weeks ]
    Past Month (current) total scores on the Clinician-Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (CAPS-5)


Secondary Outcome Measures :
  1. Change in C-reactive protein (CRP) level [ Time Frame: 12 weeks ]
    Measure of inflammation

  2. Change in interleukin 6 (IL-6) level [ Time Frame: 12 weeks ]
    Measure of inflammation

  3. Change in tumor necrosis factor alpha (TNF-α) level [ Time Frame: 12 weeks ]
    Measure of inflammation

  4. Depression Symptoms [ Time Frame: 12 weeks ]
    Total scores on the Beck Depression Inventory-II (BDI-II)

  5. Clinical Status [ Time Frame: 12 weeks ]
    Clinical Global Impressions (CGI) Scale scores

  6. Executive Functioning (Set Shifting) [ Time Frame: 12 weeks ]
    Trail Making Test (TMT) scores

  7. Executive Functioning (Verbal Fluency) [ Time Frame: 12 weeks ]
    Controlled Oral Word Association Test (COWA) scores



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Veterans between the ages of 19 and 65 who meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for chronic PTSD.
  2. Patients who have been taking an adequate dose of selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) medication, bupropion, or mirtazapine for a minimum of 8 weeks at the time of study entry.
  3. PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (PCL-5) score of > 33 at the Screening Visit. Eligible persons will be allowed to have other symptoms that are commonly comorbid with PTSD (e.g., anxiety, somatic symptoms). This strategy will provide a feasible and generalizable sample of those with chronic PTSD.

Exclusion Criteria:

  1. Patients with a concurrent DSM-5 diagnosis in any of the following categories:

    1.1. Major Neurocognitive Disorder (NCD) 1.2. Lifetime Schizophrenia and other Psychotic Disorders 1.3. Lifetime Bipolar Disorder 1.4. Alcohol Dependence or Abuse in 3 months prior to the Screening Visit 1.5. Any other Substance Dependence or Abuse (excluding nicotine) in 12 months prior to the Screening Visit 1.6. Any other concurrent Axis I Disorder (including Major Depressive Disorder) must be secondary to the primary diagnosis of PTSD.

  2. Chronic pain levels requiring use of any opiate medications with the exception of Tramadol. Patients are allowed the use of Tramadol at 25-50 mg per day dosing.
  3. Any condition or disorder that may cause neuropsychiatric sequelae (e.g., Parkinson's disease, stroke, seizures, or TBI).
  4. Past chronic PTSD, meaning PTSD that preceded the incident traumatic event responsible for the current PTSD. Other traumatic life events will not be exclusionary unless they resulted in previous PTSD.
  5. Patients with a history of intolerance or hypersensitivity to minocycline or other tetracycline antibiotics, or prior tetracycline use 2 months prior to the Screening Visit.
  6. Concomitant treatment with penicillin or other antibiotics, or treatment with antibiotics for greater than 7 days in the past month.
  7. Use of aspirin, non-steroidal anti-inflammatory agents (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors for < 6 months prior to study entry or dose changes after study entry. Limited as-needed use is permitted prior to study entry but not during the study.
  8. Use of statins will not be permitted during the study as they have been shown to reduce levels of pro-inflammatory cytokines.
  9. Use of concomitant anti-coagulant drugs (except low-dose aspirin) as minocycline has been shown to depress plasma prothrombin activity.
  10. Any degree of hepatic or renal failure that in the Investigator's judgement would pose a safety risk for treatment with minocycline.
  11. Conditions which may be negatively affected by minocycline treatment, such as active inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease).
  12. A history of C. difficile colitis.
  13. Patients who based on history or mental status examination have a significant risk of committing suicide, or who are homicidal or violent and who are in the Investigator's opinion in significant imminent risk of hurting others.
  14. Patients who have a medical condition that, in the Investigator's opinion, would expose them to an increased risk of a significant adverse event or interfere with assessments of safety and efficacy during the course of the trial.
  15. Women who are pregnant or plan to become pregnant during the study. All women of childbearing potential must have a negative urine pregnancy test at the Screening Visit and throughout the study. Sexually active women participating in the study must use a medically acceptable form of contraception.
  16. Patients with a current known infection or who are acutely ill.
  17. Patients with an autoimmune disease (i.e., Lupus, Rheumatoid Arthritis).
  18. Immunocompromised patients (i.e., HIV).
  19. Patients with thyroid disorders unless euthyroid at screening.
  20. Patients with cancer not in remission.
  21. Patients with cardiovascular disease, such as myocardial infarction and arrhythmias.
  22. Patients with diabetes.
  23. History of significant esophagitis.
  24. Patients who plan to initiate or terminate any psychotropic medication during the study. Patients taking any psychotropic medication should be on a stable dose for at least 6 weeks prior to the Screening Visit (except for the SSRI, SNRI or mirtazapine used to treat their PTSD) AND agree not to discontinue or otherwise alter treatment during the study.
  25. Patients who plan to initiate or terminate any form of psychotherapy or behavior therapy during the study with the exception of PTSD Orientation Group. Subjects may be in supportive psychotherapy if it was initiated at least three months prior to the Screening Visit AND subject agrees not to discontinue or otherwise alter therapy during the study. Subjects receiving evidence-based psychotherapies such as Prolonged Exposure or Cognitive Processing Therapy will be excluded.
  26. Patients who are unable to speak, read, and understand English or are judged by the Investigator to be unable or unlikely to follow the study protocol and complete all scheduled visits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03340350


Contacts
Contact: Sriram Ramaswamy, MD 402-995-4712 sriram.ramaswamy@va.gov

Locations
United States, Nebraska
VA Nebraska-Western Iowa Health Care System Recruiting
Omaha, Nebraska, United States, 68105
Principal Investigator: Sriram Ramaswamy, MD         
Sponsors and Collaborators
Sriram Ramaswamy
Creighton University
Investigators
Principal Investigator: Sriram Ramaswamy, MD VA Nebraska Western Iowa Health Care System

Responsible Party: Sriram Ramaswamy, Staff Psychiatrist, VA Nebraska Western Iowa Health Care System
ClinicalTrials.gov Identifier: NCT03340350     History of Changes
Other Study ID Numbers: RAM-01068
First Posted: November 13, 2017    Key Record Dates
Last Update Posted: May 1, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Sriram Ramaswamy, VA Nebraska Western Iowa Health Care System:
Minocycline
PTSD

Additional relevant MeSH terms:
Stress Disorders, Traumatic
Stress Disorders, Post-Traumatic
Trauma and Stressor Related Disorders
Mental Disorders
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents